Randomized trial · people

Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this head-to-head trial, dulaglutide lowered blood sugar and weight, but less than semaglutide at both dose levels compared, with gut side effects common on both.

Kind
Randomized trial
Studied in
People
Number studied
1201
Published
2018
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether once-weekly semaglutide controls blood sugar at least as well as once-weekly dulaglutide and lowers body weight more, in people with type 2 diabetes.

How the study was done

A randomized, open-label trial (patients and doctors knew which drug was given) at 194 sites in 16 countries, in 1201 adults with type 2 diabetes not well controlled on metformin alone. Each person got one of four weekly shots for 40 weeks: dulaglutide at a low (0.75 mg) or high (1.5 mg) dose, or semaglutide at a low (0.5 mg) or high (1.0 mg) dose.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c, a 3-month average of blood sugar, fell by 1.1 percentage points in the dulaglutide 0.75 mg arm and 1.4 points in the dulaglutide 1.5 mg arm, against 1.5 and 1.8 points with semaglutide 0.5 mg and 1.0 mg. Body weight fell by 2.3 kg with dulaglutide 0.75 mg and 3.0 kg with dulaglutide 1.5 mg, against 4.6 kg and 6.5 kg with the matching semaglutide doses; the estimated treatment differences favored semaglutide (-2.26 kg and -3.55 kg). Gut-related side effects were the most common problem: 33% of the dulaglutide 0.75 mg arm and 48% of the dulaglutide 1.5 mg arm, against 43% and 44% with semaglutide, and they were the top reason people stopped either drug. There were six deaths, two in each dulaglutide group and one in each semaglutide group.

What it doesn’t show

The trial was open-label and lasted 40 weeks, and everyone was also taking metformin, so it does not show results over longer periods or in other treatment settings. It was funded by Novo Nordisk.

The paper

Pratley et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.

The compounds

More studies on Dulaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo